US 11,938,123 B2
Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers
Jeong Hyeok Yoon, Yongin-Si (KR); and Ky Youb Nam, Goyang-Si (KR)
Assigned to PHAROS IBIO CO., LTD., (KR)
Appl. No. 17/059,046
Filed by Pharos iBio Co., Ltd., Anyang-si (KR)
PCT Filed May 29, 2019, PCT No. PCT/KR2019/006403
§ 371(c)(1), (2) Date Nov. 25, 2020,
PCT Pub. No. WO2019/231220, PCT Pub. Date Dec. 5, 2019.
Claims priority of application No. 10-2018-0061786 (KR), filed on May 30, 2018.
Prior Publication US 2021/0205290 A1, Jul. 8, 2021
Int. Cl. A61K 31/4535 (2006.01); A23L 33/10 (2016.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/4535 (2013.01) [A23L 33/10 (2016.08); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 5 Claims
 
1. A method for treating breast cancer, the method comprising a step of administering to a subject in need thereof pharmaceutical composition containing a compound represented by the following Formula 1 or a pharmaceutically acceptable salt thereof,
wherein the breast cancer is triple-negative breast cancer or Herceptin-resistant breast cancer:

OG Complex Work Unit Chemistry